Get the Stockscreener App
6.9953
0.85%
-0.0547
Day One Biopharmaceuticals Inc stock is traded at $6.9953, with a volume of 777.16K.
It is down -0.85% in the last 24 hours and down -6.92% over the past month.
Day One Biopharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is dedicated towards developing and commercializing targeted therapies for patients of all ages with genetically defined cancers. Initially, it focuses on clinical development efforts on pediatric patients living with cancer, a vulnerable population that has been underserved in the recent revolution in targeted therapeutics and immuno-oncology. The product candidate, DAY101, is an oral, brain-penetrant, highly-selective type II pan-rapidly accelerated fibrosarcoma, or pan-RAF, and kinase inhibitor.
See More
Previous Close:
$7.05
Open:
$7.08
24h Volume:
777.16K
Relative Volume:
0.54
Market Cap:
$716.01M
Revenue:
$187.64M
Net Income/Loss:
$-95.00M
P/E Ratio:
-7.3635
EPS:
-0.95
Net Cash Flow:
$-69.02M
1W Performance:
+1.75%
1M Performance:
-6.92%
6M Performance:
-8.15%
1Y Performance:
-50.07%
1-Day Range:
$6.98
$7.16
1-Week Range:
$6.665
$7.16
52-Week Range:
$5.635
$16.76
Day One Biopharmaceuticals Inc Stock (DAWN) Company Profile
Name
Day One Biopharmaceuticals Inc
Sector
Industry
Phone
650 484-0899
Address
2000 SIERRA POINT PARKWAY, SUITE 501, BRISBANE
Compare DAWN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DAWN
Day One Biopharmaceuticals Inc
|
6.9901 | 722.15M | 187.64M | -95.00M | -69.02M | -0.95 |
|
VRTX
Vertex Pharmaceuticals Inc
|
403.35 | 100.41B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
605.50 | 59.59B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.85 | 59.77B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
773.50 | 45.14B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
343.61 | 37.42B | 3.81B | -644.79M | -669.77M | -6.24 |
Day One Biopharmaceuticals Inc Stock (DAWN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-19-25 | Initiated | Piper Sandler | Overweight |
| Oct-09-24 | Reiterated | Needham | Buy |
| Aug-01-24 | Upgrade | BofA Securities | Underperform → Buy |
| Apr-24-24 | Reiterated | Needham | Buy |
| Apr-25-23 | Downgrade | BofA Securities | Buy → Underperform |
| Feb-08-23 | Initiated | CapitalOne | Overweight |
| Feb-03-23 | Initiated | Oppenheimer | Perform |
| Dec-15-22 | Initiated | H.C. Wainwright | Buy |
| Dec-14-22 | Initiated | Needham | Buy |
| Dec-05-22 | Initiated | Goldman | Buy |
| Dec-01-22 | Initiated | BofA Securities | Buy |
View All
Day One Biopharmaceuticals Inc Stock (DAWN) Latest News
Is Day One Biopharmaceuticals Inc. stock oversold or undervaluedJuly 2025 Big Picture & Low Drawdown Investment Ideas - newser.com
What analysts say about Day One Biopharmaceuticals Inc stockSupport Zone Identification & High Profit Market Ideas - earlytimes.in
How to read the order book for Day One Biopharmaceuticals Inc.Earnings Trend Report & Scalable Portfolio Growth Methods - newser.com
Can volume confirm reversal in Day One Biopharmaceuticals Inc.Weekly Loss Report & Verified Momentum Watchlists - newser.com
Smart tools for monitoring Day One Biopharmaceuticals Inc.’s price action - newser.com
Live market analysis of Day One Biopharmaceuticals Inc.2025 Price Targets & Weekly High Momentum Picks - newser.com
What drives Day One Biopharmaceuticals Inc stock priceMarket Sentiment Shifts & Maximize ROI With Proven Growth Stocks - earlytimes.in
What makes Day One Biopharmaceuticals Inc. stock attractive to growth fundsGap Down & Fast Moving Stock Watchlists - newser.com
H.C. Wainwright reiterates Buy rating on Day One Biopharmaceuticals stock By Investing.com - Investing.com Canada
Day One Biopharmaceuticals, Inc. (NASDAQ:DAWN) Given Average Rating of "Buy" by Analysts - MarketBeat
Institutional scanner results for Day One Biopharmaceuticals Inc.July 2025 Opening Moves & AI Optimized Trade Strategies - newser.com
Rhumbline Advisers Boosts Stock Position in Day One Biopharmaceuticals, Inc. $DAWN - Defense World
Real time scanner hits for Day One Biopharmaceuticals Inc. explainedPortfolio Growth Summary & Low Risk Growth Stock Ideas - newser.com
Can Day One Biopharmaceuticals Inc. hit a new high this monthPortfolio Risk Summary & Community Driven Trade Alerts - newser.com
Custom watchlist performance reports with OCCIJuly 2025 Decliners & Verified Short-Term Plans - newser.com
What is NanoViricides Inc.’s TAM (Total Addressable Market)July 2025 Chart Watch & High Accuracy Trade Alerts - خودرو بانک
Tech Rally: Is Day One Biopharmaceuticals Inc.’s growth already priced in2025 Bull vs Bear & Weekly Momentum Stock Picks - خودرو بانک
Insider Buy: Can Day One Biopharmaceuticals Inc outperform under higher oil prices - خودرو بانک
What machine learning models say about Day One Biopharmaceuticals Inc.Fed Meeting & Weekly Momentum Picks - newser.com
Market Leaders: Can DBV Technologies SA Depositary Receipt maintain its current growth rate2025 Market Overview & Fast Entry High Yield Stock Tips - khodrobank.com
CEO Change: What are the future prospects of Day One Biopharmaceuticals IncTrade Performance Summary & Weekly Stock Breakout Alerts - khodrobank.com
Investor Mood: What’s the outlook for Day One Biopharmaceuticals Inc.’s sectorWeekly Market Summary & Reliable Price Action Trade Plans - خودرو بانک
Block Trades: Will Day One Biopharmaceuticals Inc stock go up in YEAROptions Play & Real-Time Sentiment Analysis - خودرو بانک
Dynamic Technology Lab Private Ltd Acquires Shares of 48,457 Day One Biopharmaceuticals, Inc. $DAWN - MarketBeat
Earnings Update: Can Day One Biopharmaceuticals Inc outperform under higher oil prices2025 Investor Takeaways & Short-Term Swing Trade Alerts - خودرو بانک
Energy Moves: Can Day One Biopharmaceuticals Inc beat the S P 500July 2025 Spike Watch & Precise Buy Zone Identification - خودرو بانک
JonesTrading Maintains Buy Rating on Day One Biopharmaceuticals (DAWN) Following Ojemda’s FDA Approval - MSN
ETF Watch: Is Aemetis Inc. a turnaround story2025 Price Momentum & Free Expert Verified Stock Movement Alerts - خودرو بانک
Day One Biopharmaceuticals Inc Stock (DAWN) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.51%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):